Streetbeat News

CDIO

Cardio Diagnostics Holdings, Inc.

https://cardiodiagnosticsinc.com

Industry

Biotechnology

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Open

0.24

Mkt cap

11M

Volume

315K

High

0.26

P/E Ratio

-0.87

52-wk high

3.56

Low

0.24

Div yield

N/A

52-wk low

0.19

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Cardio Diagnostics Holdings (NASDAQ:CDIO) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 12:53 pm

Cardio Diagnostics has launched a redesigned website at CDIO.AI, emphasizing its AI-powered solutions for cardiovascular disease prevention, detection, and management. The new site aims to streamline access for investors, partners, patients, providers, and stakeholders.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:47 pm

Cardio Diagnostics announced that its Epi-Gen CHD Heart Attack Risk Assessment Test is now available at Meijer in McHenry, Illinois.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:32 pm

AI is being used to help cat owners in Tokyo monitor their pets' health through an app called CatsMe!, which claims to detect feline pain with over 95% accuracy. The app, developed by Carelogy and Nihon University, reflects the growing trend of AI integration in healthcare. The global AI in healthcare market is projected to reach $148.4 billion by 2029. Nvidia has also partnered with Hippocratic AI to introduce AI nurses, and Cardio Diagnostics Hldgs is using AI to prevent cardiovascular disease.

Portfolio Pulse from Ananya Gairola

June 13, 2024 | 5:51 am

Cardio Diagnostics Holdings has achieved SOC 2 Type I compliance certification for security and confidentiality, indicating a strong commitment to data protection and privacy.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:33 pm

Cardio Diagnostics Holdings received a notice from Nasdaq on June 3, indicating non-compliance with Nasdaq Listing Rule 5550(a)(2).

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 8:32 pm

Benchmark analyst Bruce Jackson maintains a Speculative Buy rating on Cardio Diagnostics Hldgs (NASDAQ:CDIO) and raises the price target from $1.35 to $2.

Portfolio Pulse from Benzinga Newsdesk

June 06, 2024 | 2:22 pm

The article highlights significant intraday movements in health care stocks on Friday. Akanda, NovaBay Pharmaceuticals, Pasithea Therapeutics, TransCode Therapeutics, Onconetix, and Doximity saw notable gains, while Lucy Scientific Discovery, SINTX Techs, Bone Biologics, ARCA biopharma, Cardio Diagnostics Holdings, and Sonoma Pharmaceuticals experienced declines.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 4:31 pm

Cardio Diagnostics Holdings, Inc. (CDIO) has expanded its clinical test offerings to Walmart's Family Medicine Specialists' Clinic in Round Lake Beach, Illinois, providing walk-in availability seven days a week. This collaboration marks a significant step for CDIO in increasing its service accessibility and presence in retail healthcare, potentially attracting a larger customer base through Walmart's extensive network.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 12:35 pm

Health care stocks experienced significant movements in Friday's intraday session, with notable gainers including Novavax, Portage Biotech, and ITeos Therapeutics, driven by their Q1 earnings reports. Conversely, Macrogenics, Revance Therapeutics, and Biofrontera were among the losers, also influenced by their Q1 earnings.

Portfolio Pulse from Benzinga Insights

May 10, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.